Multiplex RT-PCR-Based Sequencing Assay to Detect Kidney Cancer-Specific Splice Variants in Tumor Tissues and Plasma Cell-Free RNAs.
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) lacks sensitive molecular biomarkers for early detection of disease recurrence and monitoring. Downsampling analyses showed strong depth stability, with leading SVs retaining most detectability at 0.25x plasma sequencing depth (TTCB-SV = 0.99, MVK-beta-SV = 1.00, MVK-alpha-SV = 0.87, MCCC-SV = 0.93).
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) lacks sensitive molecular biomarkers for early detection of disease recurrence and monitoring. Downsampling analyses showed strong depth stability, with leading SVs retaining most detectability at 0.25x plasma sequencing depth (TTCB-SV = 0.99, MVK-beta-SV = 1.00, MVK-alpha-SV = 0.87, MCCC-SV = 0.93).
What the study was
- Study design
- Prospective study
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Molecular diagnosis & therapy
Why it surfaced
Relevant Precision oncology and genomic medicine study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.